Breast and prostate cancer diagnoses still lagging during second full year of covid-19 pandemic, quest diagnostics health trends® study finds

Analysis of more than 1.1 million test results across the united states suggests more people are living with undiagnosed cancer than before the pandemic, with potential for worse outcomes and higher healthcare costs in the future secaucus, n.j. , oct. 11, 2022 /prnewswire/ -- more than two years after the covid-19 pandemic began, diagnoses of breast and prostate cancer, two of the nation's leading causes of cancer death, continue to lag behind pre-pandemic levels, according to a nationally representative quest diagnostics health trends® study by quest diagnostics (nyse: dgx), the world's leading provider of diagnostic information services.
DGX Ratings Summary
DGX Quant Ranking